Amended Current Report Filing (8-k/a)
25 3월 2023 - 5:06AM
Edgar (US Regulatory)
0001814114
true
0001814114
2023-01-25
2023-01-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): March 24, 2023 (January 25,
2023)
ORCHESTRA BIOMED
HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-39421 |
|
92-2038755 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
150 Union Square Drive
New Hope, Pennsylvania 18938
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including
area code: (215) 862-5797
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act
|
|
Trading Symbol(s) |
|
Name of each
exchange on which registered |
Common stock, par value $0.0001 per share |
|
OBIO |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
INTRODUCTORY NOTE
This Amendment No. 1 on Form 8-K/A (“Amendment
No. 1”) amends the Current Report on Form 8-K of Orchestra BioMed Holdings, Inc., a Delaware corporation (the “Company”),
filed on January 31, 2023 (the “Original Report”), in which the Company reported, among other events, the completion of the
Business Combination (as defined in the Original Report) with Health Sciences Acquisitions Corporation 2.
This Amendment
No. 1 is being filed to include (A) the audited consolidated financial statements of Orchestra BioMed, Inc., a Delaware corporation
(“Orchestra”), at December 31, 2022 and 2021 and for the years then ended and the related notes, (B) the Management’s
Discussion and Analysis of Financial Condition and Results of Operations of Orchestra as of December 31, 2022 and for the years ended
December 31, 2022 and 2021 and (C) the unaudited pro forma condensed combined financial information
as of and for the year ended December 31, 2022.
This Amendment No. 1 does not amend any other item of the Original Report (except as otherwise expressly stated herein) or purport
to provide an update or a discussion of any developments at the Company or its subsidiaries subsequent to the filing date of the Original
Report, except as otherwise expressly stated herein.
The information previously reported in or filed with the Original Report is hereby
incorporated by reference to this Amendment No. 1. Terms used but not defined herein shall have the meanings ascribed thereto in
the Original Report. The information provided herein relates to Orchestra prior to the consummation of the Business Combination unless
otherwise specifically indicated (e.g., with respect to subsequent events disclosures, forward-looking statements, or potential
future risk factors) or the context otherwise requires.
Item 2.02. Results of Operations and Financial
Condition.
The financial statements set forth under paragraph (a)(1) of Item 9.01
of this Current Report on Form 8-K are incorporated herein by reference.
The information in this Item 2.02 is being furnished and shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference
in such filing.
Item 9.01. Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
| (1) | The consolidated financial statements of Orchestra at December 31,
2022 and 2021, and for the years then ended, and the related notes thereto, are attached as Exhibit 99.1 and are incorporated herein
by reference. |
(2) | The Management’s Discussion and Analysis of Financial
Condition and Results of Operations of Orchestra as of December 31, 2022 and for the years ended December 31, 2022 and 2021 is attached
as Exhibit 99.2 and is incorporated herein by reference. |
(b) Pro forma financial information.
The unaudited pro forma condensed combined financial information as
of December 31, 2022 and for the year ended December 31, 2022 is attached hereto as Exhibit 99.3 and is incorporated herein by reference.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ORCHESTRA BIOMED HOLDINGS, INC. |
|
|
|
By: |
/s/ David P. Hochman |
|
Name: |
David P. Hochman |
|
Title: |
Chief Executive Officer |
Date: March 24, 2023
2
Health Sciences Acquisit... (NASDAQ:HSAQ)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Health Sciences Acquisit... (NASDAQ:HSAQ)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024